Bialer Meir, Johannessen Svein I, Koepp Matthias J, Levy René H, Perucca Emilio, Tomson Torbjörn, White H Steve
Faculty of Medicine, School of Pharmacy and David R. Bloom Center for Pharmacy, Institute for Drug Research, Hebrew University of Jerusalem, Jerusalem, Israel.
National Center for Epilepsy, Sandvika, Norway.
Epilepsia. 2018 Oct;59(10):1811-1841. doi: 10.1111/epi.14557.
The Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV) took place in Madrid, Spain, on May 13-16, 2018 and was attended by 168 delegates from 28 countries. The conference provided a forum for professionals involved in basic science, clinical research, regulatory affairs, and clinical care to meet and discuss the latest advances related to discovery and development of drugs and devices aimed at improving the management of people with epilepsy. This progress report provides a summary of findings on investigational compounds for which data from preclinical or early (phase I) clinical studies were presented. The compounds reviewed include adenosine and adenosine kinase inhibitors, BIS-001 (huperzine A), 2-deoxy-d-glucose, FV-082, FV-137, JNJ-40411813, JNJ-55511118 and analogs, ketone-enhanced antiepileptic drugs, oxynytones, OV329, TAK-935 (OV935), XEN901, and XEN1101. Many innovative approaches to drug development were presented. For example, some compounds are being combined with traditional antiepileptic drugs based on evidence of synergism in seizure models, some act as inhibitors of enzymes involved in modulation of neuronal activity, and some interact in novel ways with excitatory receptors or ion channels. Some of the compounds in development target the etiology of specific epilepsy syndromes (including orphan conditions) through precision medicine, and some offer hope of producing disease-modifying effects rather than symptomatic seizure suppression. Overall, the results summarized in the report indicate that important advances are being made in the effort to develop compounds with potentially improved efficacy and safety profiles compared with existing agents.
第十四届埃拉特新型抗癫痫药物与设备会议（EILAT XIV）于2018年5月13日至16日在西班牙马德里举行，来自28个国家的168名代表出席了会议。该会议为从事基础科学、临床研究、监管事务和临床护理的专业人员提供了一个交流平台，以探讨与旨在改善癫痫患者管理的药物和设备的发现与开发相关的最新进展。本进展报告总结了关于研究性化合物的研究结果，这些化合物的临床前或早期（I期）临床研究数据在会上进行了展示。所审查的化合物包括腺苷和腺苷激酶抑制剂、BIS - 001（石杉碱甲）、2 - 脱氧 - D - 葡萄糖、FV - 082、FV - 137、JNJ - 40411813、JNJ - 55511118及其类似物、酮增强型抗癫痫药物、氧杂环丁烷、OV329、TAK - 935（OV935）、XEN901和XEN1101。会上展示了许多创新的药物开发方法。例如，一些化合物基于癫痫发作模型中的协同作用证据与传统抗癫痫药物联合使用，一些化合物作为参与调节神经元活动的酶的抑制剂发挥作用，还有一些以新颖的方式与兴奋性受体或离子通道相互作用。一些正在开发的化合物通过精准医学针对特定癫痫综合征（包括罕见病）的病因，还有一些有望产生疾病修饰作用而非仅仅对症抑制癫痫发作。总体而言，报告中总结的结果表明，在开发与现有药物相比可能具有更好疗效和安全性的化合物方面正在取得重要进展。
